SciLux podcast – Patrick and Michael Dang on Oncology

23 April 2024

Gut Microbiome, Immunotherapy & Targeted Cancer Therapy

In the field of oncology, cancer treatment options are becoming increasingly diverse. Patrick Dang and Michaël Dang both work in the field of cancer research, but have chosen different specialisations: the gut microbiome in the context of cancer immunotherapy on the one hand, and genetics to develop targeted therapies on the other.

Patrick Dang is a resident in Hemato-Oncology at the Centre Hospitalier de Luxembourg (CHL) and a PhD student at the Luxembourg Center for Systems Biomedicine (LCSB) of the University of Luxembourg. His research work aims to resolve the microbiome-derived molecular complex in the gut and its impact on the human immune system in the context of cancer immunotherapy.

Michael Dang is a resident in oncology and Translational medical oncology at the National Center for Tumour Diseases (NCT) in Heidelberg, Germany, where he translates research into clinical practice.

Listen to Patrick and Michael Dang to learn more about cancer research and more especially gut microbiome research in the context of cancer immunotherapy and targeted therapies based on genetics.

Listen to the new SciLux episode

Gut Microbiome Research in Luxembourg

Through his research on the microbiome-derived molecular complex in the gut, Patrick Dang’s primary goal is to identify differences in microbiome molecular signatures between responders and non-responders using integrative multi-omics approaches. Specifically, the aim is to identify differences in the abundance of taxonomic species and to link the expression of disease-associated microbial functions to different taxa.

Luxembourg has developed a strong expertise in research around the gut microbiome. From research to business solutions, Luxembourg is internationally recognised as a hub in this field.

Shifts in human gut microbiome due to COVID-19

Babies and their gut microbiome tell a story

What microbes really do in our guts

Cancer Research in Luxembourg

Cancer immunotherapy research is increasingly linked to genetics. Today, instead of standard chemotherapy, we are introducing targeted therapies based on mutations found in patients’ tumours.

Luxembourg has specialised in this kind of personalised healthcare, focusing on personalised cancer treatment for each patient.

A new breakthrough in cancer treatment

Cutting-edge research in Luxembourg: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing Genes

Cancer Research

A podcast to highlight research made in Luxembourg

Research Luxembourg and SciLux have teamed up to launch a new series of podcasts showcasing science in Luxembourg and beyond.

With a new episode every 2 weeks published, ‘SciLux powered by Research Luxembourg’ will showcase research activities and scientific cooperation in Luxembourg.

Learn more on the SciLux X Research Luxembourg podcast